AU595504B2 - Phenyl carbamates - Google Patents

Phenyl carbamates Download PDF

Info

Publication number
AU595504B2
AU595504B2 AU54284/86A AU5428486A AU595504B2 AU 595504 B2 AU595504 B2 AU 595504B2 AU 54284/86 A AU54284/86 A AU 54284/86A AU 5428486 A AU5428486 A AU 5428486A AU 595504 B2 AU595504 B2 AU 595504B2
Authority
AU
Australia
Prior art keywords
methyl
hydrogen
compounds
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU54284/86A
Other languages
English (en)
Other versions
AU5428486A (en
Inventor
Michael Chorev
Zeev Tashma
Marta Weinstock-Rosin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proterra AG
Original Assignee
Proterra AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU595504(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proterra AG filed Critical Proterra AG
Publication of AU5428486A publication Critical patent/AU5428486A/en
Application granted granted Critical
Publication of AU595504B2 publication Critical patent/AU595504B2/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AU54284/86A 1985-03-05 1986-03-05 Phenyl carbamates Expired AU595504B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
IL74497 1985-03-05

Publications (2)

Publication Number Publication Date
AU5428486A AU5428486A (en) 1986-09-11
AU595504B2 true AU595504B2 (en) 1990-04-05

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54284/86A Expired AU595504B2 (en) 1985-03-05 1986-03-05 Phenyl carbamates

Country Status (25)

Country Link
US (1) US4948807A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0193926B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS61225158A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR940010764B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE58130T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU595504B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1284501C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1748A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE19875046I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK172851B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8801193A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI87197C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR860586B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK130293A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU201297B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE58838B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL74497A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU90312I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY137602A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL980031I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ215348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH23325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL146301B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT82127B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA861653B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
PT951284E (pt) * 1996-12-18 2003-12-31 Yissum Res Dev Co Derivados de feniletilamina
JP4222632B2 (ja) 1996-12-18 2009-02-12 テバ・ファーマシューティカル・インダストリーズ・リミテッド アミノインダン誘導体
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
WO1998031356A1 (en) * 1997-01-17 1998-07-23 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
EP2311441A1 (en) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
CN105112463A (zh) 2000-01-28 2015-12-02 Dsmip资产公司 通过在发酵罐中高密度培养真核微生物来增加含有多烯脂肪酸的脂质的产生
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2133078A1 (en) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
WO2003101917A2 (en) * 2002-05-31 2003-12-11 Sun Pharmaceutical Industries Limited A process for the preparation of phenylcarbamates
WO2003105830A1 (ja) 2002-06-14 2003-12-24 富山化学工業株式会社 脳機能を改善する医薬組成物および脳機能を改善するための方法
MXPA05003715A (es) * 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
CZ20023555A3 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
CA2543322A1 (en) * 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
DE602004028150D1 (de) 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2005072713A2 (en) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
CA2555386A1 (en) * 2004-02-19 2005-09-01 Novartis Ag Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1812007B1 (en) * 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US8158627B2 (en) * 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CN101631547A (zh) 2006-10-27 2010-01-20 梅迪维新神经学公司 使用地莫本和多奈哌齐治疗阿尔茨海默病的组合疗法
WO2008097546A2 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
WO2008124969A1 (fr) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Méthode de préparation de rivastigmine et de ses intermédiaires
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6334511B2 (ja) 2012-04-14 2018-05-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規方法
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
JPH0255416B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-11-27
EP0193926B1 (en) 1990-11-07
HK130293A (en) 1993-12-03
ZA861653B (en) 1987-10-28
DE19875046I1 (de) 2003-09-04
NL980031I2 (nl) 1999-03-01
NZ215348A (en) 1990-04-26
JPS61225158A (ja) 1986-10-06
EP0193926B3 (en) 2010-04-28
EP0193926A3 (en) 1987-05-13
IE860558L (en) 1986-09-05
IL74497A (en) 1990-02-09
FI87197C (fi) 1992-12-10
CY1748A (en) 1994-06-03
KR940010764B1 (ko) 1994-11-11
ES8801193A1 (es) 1988-01-01
US4948807A (en) 1990-08-14
ES552627A0 (es) 1988-01-01
FI860914A0 (fi) 1986-03-04
PH23325A (en) 1989-07-14
NL980031I1 (nl) 1999-01-04
FI860914L (fi) 1986-09-06
DK172851B1 (da) 1999-08-16
PL146301B1 (en) 1989-01-31
PT82127A (en) 1986-04-01
IE58838B1 (en) 1993-11-17
LU90312I2 (fr) 1999-01-06
DE3675408D1 (de) 1990-12-13
PT82127B (pt) 1988-07-01
CY2004004I1 (el) 2009-11-04
DK99186D0 (da) 1986-03-04
EP0193926A2 (en) 1986-09-10
CY2004004I2 (el) 2009-11-04
GR860586B (en) 1986-07-07
MY137602A (en) 2009-02-27
CA1284501C (en) 1991-05-28
HUT41718A (en) 1987-05-28
ATE58130T1 (de) 1990-11-15
AU5428486A (en) 1986-09-11
IL74497A0 (en) 1985-06-30
DK99186A (da) 1986-09-06
HU201297B (en) 1990-10-28
KR860007207A (ko) 1986-10-08
FI87197B (fi) 1992-08-31

Similar Documents

Publication Publication Date Title
AU595504B2 (en) Phenyl carbamates
CA1307003C (en) Phenyl carbamate
RU2205007C2 (ru) Таблетки с пролонгированным выделением для лечения болезни паркинсона
CA2078028C (en) A tramadol n-oxide material, enantiomers and compositions thereof, and their use
DE69020277T2 (de) (+)-Isomere von Endoetheno/Endoethano-epoxymorphinan-Derivaten als Mittel gegen Husten.
NZ244250A (en) Analgesic composition comprising a tramadol compound and a codeine-like
EP0132346A1 (en) Novel compounds and compositions useful for producing analgesia
Weinstock et al. Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer’s disease
US4857553A (en) Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
PT1185267E (pt) Agentes anestesicos dermicos
IE62462B1 (en) Novel esters of estramustine
US4218477A (en) Primary aminoacylanilides, methods of making the same and use as antiarrhythmic drugs
Diouf et al. Anticonvulsant and neurotoxicological properties of 4-amino-N-(2-ethylphenyl) benzamide, a potent ameltolide analogue
US6962930B1 (en) Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
CN113214107B (zh) 一种芳香类化合物、制备方法及在药物中的应用
SU1517759A3 (ru) Способ получени 4-амино-2-(2-бутанон-3-ил)-окси-5-хлор-N-[2-(диэтиламино)этил]бензамида или его солей
US3976771A (en) Glycylglycine amide preparations and method of use antiarrhythmic
US6908915B1 (en) Tricyclic compounds and their uses as antiarrhythmic antifibrillatory and defibrillatory agents
BODOR et al. Sequential bioactivation of methoxime analogs of β-adrenergic antagonists in the eye
Domino The Chemistry and Pharmacology of Certain Compounds Affecting the Central Nervous System of Animals and Men
WO1997036589A9 (en) Use of 1-benzyl-1,2,3,4-tetrahyhydroisoquinoline for the manufacture of a medicament for improving cerebral function
WO1997036589A1 (en) Use of 1-benzyl-1,2,3,4-tetrahyhydroisoquinoline for the manufacture of a medicament for improving cerebral function
NO142440B (no) Analogifremgangsmaater til fremstilling av nye antiarytmisk virksomme primaere aminoacylanilider

Legal Events

Date Code Title Description
NC Extension of term for standard patent requested (sect. 70)

Free format text: FT="PRODUCT" NAME: EXELON

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: EXELON

Extension date: 20110305

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: EXELON

Extension date: 20110305